id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2005-P-0124-0005,FDA,FDA-2005-P-0124,Letter from FDA CDER to Pharmaceutical Patent Attorneys,Other,LET-Letter,2007-03-19T04:00:00Z,2007,3,,,2024-12-13T15:36:22Z,,0,0,090000648043fc3f
FDA-2005-P-0124-0004,FDA,FDA-2005-P-0124,"Determination That LAMICTAL (Lamotrigine) Tablets, 50 Milligrams and 250 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness",Notice,N-Notice,2007-03-05T05:00:00Z,2007,3,2007-03-02T05:00:00Z,,2024-12-13T15:35:05Z,,0,0,090000648043fc3e
FDA-2005-P-0124-0003,FDA,FDA-2005-P-0124,"Letter from FDA CDER to Pharmaceutical Patent Attorneys, LLC",Other,LET-Letter,2005-12-16T05:00:00Z,2005,12,,,2024-12-13T15:34:04Z,,0,0,090000648043fc3d
FDA-2005-P-0124-0002,FDA,FDA-2005-P-0124,"Acknowledgment Letter from FDA DDM to Pharmaceutical Patent Attorneys, LLC",Other,Acknowledgement Letter/Receipt,2005-06-16T04:00:00Z,2005,6,,,2024-12-13T15:32:45Z,,0,0,090000648043fc3c
FDA-2005-P-0124-0001,FDA,FDA-2005-P-0124,"Acknowledgment Letter from FDA DDM to Pharmaceutical Patent Attorneys, LLC",Other,Acknowledgement Letter/Receipt,2005-06-16T04:00:00Z,2005,6,,,2024-12-13T15:31:35Z,,0,0,090000648043fc2d